N-acetylcysteine for LPRD

The use of inhaled N-acetylcysteine for laryngopharyngeal reflux disease: A randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0004099

Enrollment

Registered

2019-06-27

Start date

2016-06-30

Completion date

Unknown

Last updated

2019-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : control group: oral rabeprazole 20mg once daily , for 2 months study group: oral rabeprazole 20mg once daily and inhaled N-acetylcysteine 20&#37

, 4ml twice a day , for 2 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. symptoms of LPRD : globus (a sensation of a lump in the throat), throat clearing, hoarseness, postnasal drip (PND) sense and cough 2. reflux symptom index (RSI) greater than 13 3. reflux finding scores (RFS) greater than 7

Exclusion criteria

Exclusion criteria: patients with acute or chronic sinusitis or with symptoms of upper respiratory infection at initial visit, patients with lower respiratory disease such as asthma, chronic obstructive pulmonary disease, pneumonia, or lung cancer, patients with organic lesions in the pharynx, larynx, or oral cavity such as malignancy, significant hypertrophy of palatine or lingual tonsil, or huge vallecular cyst, patients who had psychiatric history such as depression or insomnia or those taking psychiatric medication, patients older than 70 years, younger than 20 years, or pregnant, patients currently taking PPI

Design outcomes

Primary

Measure	Time frame
improvement of reflux symptom index	—

Secondary

Measure	Time frame
improvement of reflux finding score	—

Countries

Korea, Republic of

Contacts

Public ContactYoon Kyoung So

Inje University

yoonkyoung78@gmail.com+82-31-910-7250

Outcome results